

PRESS RELEASE

Elanix Biotechnologies Announces First Half 2017 Financial Results

Nyon, Switzerland and Berlin, Germany, September 29, 2017 -- [Elanix Biotechnologies AG](#) (FRA: ELN), a developer of tissue regeneration products and specialty cosmetics in dermatology and gynecology, announced today financial results for the first half 2017 ending June 30th, and provided an update on recent business progress.

First Half 2017 Financial Results

- Total revenue of EUR 77,847 compared to EUR 0 in first half 2016
- Operating Loss of EUR 1,976,839
- Cash and cash equivalents of EUR 2,284,544 (compared to EUR 73,581 as of December 31, 2016)
- Financial guidance for 2017 remains unchanged

“Our financials for the first half of 2017 were in-line with expectations as we launched GYNrepair® topical women’s health cream on the European market on May 31, 2017. Our subsidiary, Repair-A, immediately started its promotional activities with local direct and global e-commerce sales activities,” commented Tomas Svoboda, CEO of Elanix Biotechnologies.

Business Highlights

Commercial Achievements

- Entered agreement with Apraxon to establish logistics center for storage and shipping of women’s health cream GYNrepair and support Elanix’s e-commerce platform
- Launched topical women’s health cream, GYNrepair across Europe
- Launched adherence mobile app for GYNrepair

R&D Developments

- Wholly owned subsidiary, Repair-A SA acquired an additional product candidate

Corporate Developments

- Secured capital increase of EUR 4.71 million in February 2017, with 28% oversubscription
- Expanded Elanix team with key positions

First Half 2017 Financial Review

Key audited consolidated figures for the six months ended June 30, 2017
(in Thousands of EURs, except per share data)

	2017	2016	Change	Change as a %
Revenue	78	0	n/a	n/a
Gross Profit	59	0	n/a	n/a
Operating Loss Before Financial Expenses	(2,036)	(940)	(1,096)	46%
Operating profit/(loss)	(1,977)	(940)	(1,037)	
Net Income/(loss)	(1,677)	(784)	(893)	
Earnings per share, diluted	(0.26)	(0.15)	(0.11)	

Financial Guidance 2017

Elanix reaffirms its financial guidance for 2017 as published in the 2016 annual report. The forecast reflects Elanix's continued focus on the core business of wound care products. The Company confirms its expectations for total revenue of EUR 300,000 – EUR 500,000 in 2017.

Elanix Biotechnologies AG (FRA: ELN) develops and commercializes tissue regeneration products for acute wound care, dermatological and gynaecological applications, and provides services in cell technologies. The company was founded in 2012 as a spin-out from the University Hospital of Lausanne (CHUV), Switzerland, to commercialize a patented human progenitor cell technology. Progenitor cells are fully differentiated yet immunologically neutral cells that are very potent inducers of tissue growth and healing. Elanix owns GMP certified Master and Working human cell banks with vast quantities of cells.

Elanix is headquartered in Nyon, Switzerland, with its registered office in Berlin, Germany, and listed on the Frankfurt Stock Exchange under the symbol ELN. For more information and updates, visit www.elanixbiotechnologies.com.

Press Contacts:

Elanix Biotechnologies AG

Tomas Svoboda, CEO

Tel: +41 22 363 66 40

investor.relations@elanix-bt.com

Halsin Partners

Mike Sinclair

Tel: +44 (0)20 7318 2955

msinclair@halsin.com

Disclaimer / Forward-looking statements:

This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.